AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025.

Akebia-supported posters will be displayed at NKF SCM25 during Exhibit Hall hours.

  • Cardiovascular Risk in Patients With DD-CKD Randomized to Vadadustat vs Darbepoetin Alfa With or Without Cardiovascular Disease:



  • Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD:

On Thursday, April 10, 2025 at 4:00 pm during at NKF SCM25, Dr. Wolfgang Winkelmayer will present a poster titled “Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD.”

NKF SCM25 attendees can also visit Akebia at Booth #1121 in the Exhibit Hall.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at , which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco



EN
25/03/2025

Underlying

AKBAAkebia Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akebia Therapeutics Inc.

 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financia...

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclero...

February 26, 2026 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financ...

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights Akebia to Host Conference Call on February 26 at 8:00 a.m. EST CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets. Akebia will host a conference call on Thursday, February 26, 2026, at 8:00 a.m. EST to discuss its financial results and recent business highlights. T...

February 19, 2026 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Bio...

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12 at 9:30 AM EST. A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at following the conference. The Emerging Outlook: ...

February 4, 2026 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rul...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 132,675 shares of Akebia’s common stock on January 30, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exerci...

February 2, 2026 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outl...

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook  Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomerulosclerosis (FSGS) AKB-097 Phase 2 rare kidney disease basket trial scheduled to begin in 2H 2026 with initial data expected in 2027 CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch